Goldman Sachs Group Inc. reiterated their neutral rating on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a report released on Tuesday morning. Goldman Sachs Group Inc. currently has a $80.00 target price on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on GILD. Citigroup Inc. reissued a buy rating and set a $105.00 target price on shares of Gilead Sciences in a report on Tuesday, May 31st. Gabelli began coverage on shares of Gilead Sciences in a report on Wednesday, June 1st. They set a buy rating and a $109.00 target price on the stock. Robert W. Baird reissued an outperform rating and set a $135.00 target price on shares of Gilead Sciences in a report on Monday, June 6th. Morgan Stanley reissued a hold rating on shares of Gilead Sciences in a report on Monday, June 6th. Finally, Maxim Group reissued a hold rating on shares of Gilead Sciences in a report on Wednesday, June 8th. Ten analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $104.63.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 79.12 on Tuesday. Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11. The company has a 50 day moving average of $79.40 and a 200 day moving average of $85.53. The firm has a market cap of $104.41 billion, a PE ratio of 6.94 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $3.15 earnings per share. On average, equities research analysts anticipate that Gilead Sciences will post $11.76 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.38%. Gilead Sciences’s payout ratio is 16.56%.
In related news, EVP Paul Rutherford Carter sold 2,000 shares of the firm’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $79.81, for a total value of $159,620.00. Following the completion of the transaction, the executive vice president now directly owns 64,122 shares of the company’s stock, valued at $5,117,576.82. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total value of $409,200.00. Following the completion of the transaction, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at $10,881,773.76. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $427,750,000. Capital World Investors boosted its position in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares during the period. Investec Asset Management LTD purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $280,342,000. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares during the period. Finally, NN Investment Partners Holdings N.V. purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $180,268,000. 77.94% of the stock is owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.